AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback
On July 27, AstraZeneca PLC will report its results for the second quarter of 2026. As a reminder, its revenue rose 12.5% year-over-year to $15.29 billion in Q1. Enhertu, one of the key growth drivers of AstraZeneca's oncology franchise, generated $831 million in revenue in Q1, up 39.4% YoY and 4.1% QoQ.
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill developed by China's Dizal Pharmaceutical. The Cambridge-based drugmaker could pay a further $900 million if the treatment hits certain development, regulatory and sales targets.
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
AstraZeneca entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment.
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage
Astrazeneca NYSE: AZN told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned from existing programs.
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
The latest trading day saw Astrazeneca (AZN) settling at $171.61, representing a -3.85% change from its previous close.
AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic
AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and in line for royalties on sales of eplontersen, also fell by >20%. AZN's ambitious $80bn 2030 revenue target now faces a ~$15bn gap by my calculation, but a robust late-stage pipeline and strong oncology division provide resilience.
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.
AstraZeneca's Wainua failure hurts credibility more than valuation, Jefferies warns
The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainua's trial failure is less about the numbers than about a dent to management's credibility, according to Jefferies. The shares fell 9% and topped the FTSE 100 fallers' list, a move the broker expects to exceed the drug's actual contribution to valuation.
5 Things to Know Before the Stock Market Opens on Thursday
Stock futures are slightly higher this morning as investors monitor developments in the Middle East; PepsiCo's results narrowly beat Wall Street estimates as strength in international markets offset sluggish sales in North America; Korean memory chip maker SK Hynix is reportedly seeing heavy demand for its upcoming U.S. stock listing; AstraZeneca shares are sinking after a disappointing heart drug trial; and Levi Strauss shares are falling after the denim apparel maker issued weak guidance. Here's what you need to know today.
UK stocks decline as AstraZeneca tumbles after trial setback
The UK's FTSE 100 declined on Thursday as investors assessed renewed tensions in the Middle East, while pharmaceutical heavyweight AstraZeneca weighed heavily on the benchmark after reporting disappointing results from a late-stage clinical trial. The blue-chip FTSE 100 index fell 0.6% to 10,417.63 points by 10:45 GMT.
